Summed and weighted summary scores for the medsger disease severity scale compared with the physician's global assessment of disease severity in systemic sclerosis

Journal of Rheumatology

Volumn 43, Issue 8, 2016, Pages 1510-1518

  Harel, Daphna ^a   Hudson, Marie ^b,c   Iliescu, Alexandra ^b   Baron, Murray ^b,c   Steele, Russell ^b,c  

^a NEW YORK UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Disease severity scleroderma; Disease severity score; Outcome assessment; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONSTRUCT VALIDITY; CONTROLLED STUDY; CONVERGENT VALIDITY; DISCRIMINATIVE VALIDITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDSGER DISEASE SEVERITY SCALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT OF DISEASE SEVERITY SCORE; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RATING SCALE; SCORING SYSTEM; SUMMED SUMMARY SCORE; SYSTEMIC SCLEROSIS; VALIDITY; WEIGHTED SUMMARY SCORE; AGED; FACTUAL DATABASE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 84982797274     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.151440     Document Type: Article

References (36)

1. Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995;7:517-21.
2. Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000;12:545-8.
3. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
4. Symmons DP. Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol 1995;9:267-85.
5. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
6. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21 Suppl 29:S39-41.
7. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21 Suppl 29:S42-6.
8. Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004;33:249-63.
9. Hudson M, Impens A, Baron M, Seibold JR, Thombs BD, Walker JG, et al; Canadian Scleroderma Research Group. Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol 2010;37:2307-12.
10. Fan X, Pope J, Baron M; Canadian Scleroderma Research Group. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2010;30:1205-10.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
12. Rimar D, Rosner I, Nov Y, Slobodin G, Rozenbaum M, Halasz K, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol 2014;66:726-30.
13. Gheita T, Hussein H. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap. Joint Bone Spine 2012;79:51-6.
14. Hinchcliff ME, Beaumont JL, Carns MA, Podlusky S, Thavarajah K, Varga J, et al. Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short-forms in systemic sclerosis. J Rheumatol 2015;42:64-72.
15. Hinchcliff ME, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, et al. Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res 2011;63:1620-8.
16. Alhajeri H, Hudson M, Fritzler M, Pope J, Tatibouet S, Markland J, et al. 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Arthritis Care Res 2015;67:582-7.
17. Matthews WB. Medical Research Council. Aids to the examination of the peripheral nervous system [abstract]. [Internet. Accessed May 2, 2016.] Available from: www.jns-journal.com/article/0022-510X(77)90205-2/abstract
18. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007;34:1528-34.
19. Hudson M, Walker JG, Fritzler M, Taillefer S, Baron M. Hypocomplementemia in systemic sclerosis-clinical and serological correlations. J Rheumatol 2007;34:2218-23.
20. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
21. Diab S, Dostrovsky N, Hudson M, Tatibouet S, Fritzler MJ, Baron M, et al. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol 2014;41:2179-85.
22. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
23. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
24. Van Tubergen A, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 2002;47:242-8.
25. Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990;17:1022-4.
26. Johnson SR, Hawker GA, Davis AM. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Care Res 2005;52:256-62.
27. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
28. Muraki E. A generalized partial credit model: application of an EM algorithm. Appl Psychol Meas 1992;16:159-76.
29. Glas CA. Detection of differential item functioning using Lagrange multiplier tests. Stat Sin 1998;8:647-67.
30. Harel D. The effect of model misspecification for polytomous logistic adjacent category item response theory models [dissertation]. Montreal: McGill University; 2014:142.
31. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet. Accessed May 2, 2016.] Available from: www.R-project.org
32. Rizopoulos D. ltm: an R package for latent variable modeling and item response theory analyses. J Stat Softw 2006;17:1-25.
33. Plummer M. rjags: Bayesian Graphical Models using MCMC. R package version 3-15. [Internet. Accessed May 2, 2016.] Available from: CRAN.R-project.org/package=rjags
34. Su Y, Yajima M. R2jags: Using R to run 'JAGS'. R package version 0.5-6. [Internet. Accessed May 2, 2016.] Available from: CRAN.R-project.org/package=R2jags
35. Therneau T. A Package for survival analysis in S. R package version 2.37-7. [Internet. Accessed May 2, 2016.] Available from: cran.r-project.org/package=survival
36. White H. Maximum likelihood estimation of misspecified models. Econometrica 1982;50:1-25.